CyPath Lung test sales hit new high at bioAffinity Technologies (NASDAQ: BIAF)

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. reported that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025. The company disclosed this business update through a press release, which is furnished as an exhibit to this report.

The filing does not include detailed financial figures, but highlights growing adoption of the CyPath® Lung test as a notable operating milestone for the period.

false 0001712762 0001712762 2025-10-07 2025-10-07 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-10-07 2025-10-07 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-10-07 2025-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 7, 2025, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated October 7, 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 7, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did bioAffinity Technologies (BIAF) announce about CyPath Lung sales?

bioAffinity Technologies announced that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025. This update was shared via a press release furnished as an exhibit to the current report.

Which product is highlighted in bioAffinity Technologies’ October 2025 8-K filing?

The filing highlights CyPath® Lung, bioAffinity Technologies’ diagnostic test for lung cancer. The company stated that sales of this test reached a new high in the third quarter of 2025, and it issued a press release describing this development.

Does bioAffinity Technologies’ October 7, 2025 report include detailed financial results?

The report does not present detailed financial statements or earnings data. It focuses on announcing that CyPath® Lung diagnostic test sales reached a new high in the third quarter of 2025, as described in an attached press release exhibit.

What exhibit is attached to bioAffinity Technologies’ October 7, 2025 current report?

The report includes Exhibit 99.1, a press release issued by bioAffinity Technologies dated October 7, 2025. This exhibit describes that sales of the company’s CyPath® Lung diagnostic test for lung cancer reached a new quarterly high.

On which market is bioAffinity Technologies common stock traded?

bioAffinity Technologies’ common stock, with par value $0.007 per share, is listed on The Nasdaq Stock Market LLC, specifically the Nasdaq Capital Market, under the trading symbol BIAF, as indicated in the company’s current report.

What trading symbols are associated with bioAffinity Technologies securities?

The company lists its common stock under the symbol BIAF on the Nasdaq Capital Market. Warrants to purchase common stock are listed separately under the trading symbol BIAFW, according to the registration table included in the current report.